

SUPPLEMENTARY INFORMATION

Neutralizing antibody titres in SARS-CoV-2 infections

Eric HY Lau¹, Owen TY Tsang,² David SC Hui,³ Mike YW Kwan,⁴ Wai-hung Chan,⁵ Susan S Chiu,⁶ Ronald LW Ko¹, Kin H Chan¹, Samuel M.S. Cheng¹, Ranawaka APM Perera¹, Benjamin J Cowling¹, Leo LM Poon¹, Malik Peiris^{1,7,*}.

1. School of Public Health, The University of Hong Kong, Special Administrative Region of Hong Kong, China
2. Infectious Diseases Centre, Princess Margaret Hospital, Hospital Authority of Hong Kong, Special Administrative Region of Hong Kong, China.
3. Department of Medicine and Therapeutics, Prince of Wales Hospital, Chinese University of Hong Kong,
4. Department of Paediatric and Adolescent Medicine, Princess Margaret Hospital, Hospital Authority of Hong Kong, Special Administrative Region of Hong Kong, China.
5. Department of Paediatrics, Queen Elizabeth Hospital, Hospital Authority of Hong Kong, Special Administrative Region of Hong Kong, China.
6. Department of Paediatric and Adolescent Medicine, The University of Hong Kong and Queen Mary Hospital, Hospital Authority of Hong Kong, Special Administrative Region of Hong Kong, China.
7. HKU-Pasteur Research Pole, The University of Hong Kong, Special Administrative Region of Hong Kong, China.

***Address correspondence** to Dr. Malik Peiris, School of Public Health, The University of Hong Kong, Pokfulam, Hong Kong Special Administrative Region. E mail: malik@hku.hk

Key words: COVID-19, SARS-CoV-2, coronavirus, neutralizing antibody, kinetics, protection, immunity.

Supplementary Table 1. Characteristics of patients tested by plaque reduction neutralization tests (PRNT) and spike receptor binding domain ELISA.

| | PRNT | | | | ELISA | | | |
|----------------------------|----------------------|-------|---|-------|----------------------|-------|---|-------|
| | All patients (n=195) | | Patients with multiple samples for PRNT ₅₀ and PRNT ₉₀ (n=70) | | All patients (n=150) | | Patients with multiple samples for ELISA (n=55) | |
| | N | (%) | N | (%) | N | (%) | N | (%) |
| Age (y) | | | | | | | | |
| ≤15 | 42 | (22%) | 9 | (13%) | 6 | (4%) | 0 | (0%) |
| 16-60 | 119 | (61%) | 44 | (63%) | 110 | (73%) | 39 | (71%) |
| >60 | 34 | (17%) | 17 | (24%) | 34 | (23%) | 16 | (29%) |
| Male | 118 | (61%) | 38 | (54%) | 92 | (61%) | 29 | (53%) |
| With underlying conditions | 49/194 | (25%) | 16 | (23%) | 45 | (30%) | 15 | (27%) |
| Antiviral treatment | 100 | (51%) | 42 | (60%) | 92 | (61%) | 38 | (69%) |
| Corticosteroid treatment | 12 | (6%) | 7 | (10%) | 12 | (8%) | 7 | (13%) |
| Worst condition | | | | | | | | |
| Severe | 13 | (7%) | 9 | (13%) | 13 | (9%) | 9 | (16%) |
| Mild | 151 | (77%) | 52 | (74%) | 128 | (85%) | 45 | (82%) |
| Asymptomatic | 31 | (16%) | 9 | (13%) | 9 | (6%) | 1 | (2%) |

Supplementary Table 2: Severity by age

| Age groups | Severity | | |
|------------|-----------|-----------|--------------|
| | Severe | Mild | Asymptomatic |
| ≤15 | 0 (0%) | 24 (16%) | 18 (58%) |
| 15-60 | 3 (18%) | 104 (69%) | 12 (29%) |
| >60 | 10 (82%) | 23 (15%) | 1 (3%) |
| Total | 13 (100%) | 151 (100) | 31 (100%) |

Supplementary Table 3: Sera tested and positive by PRNT and ELISA stratified by days after onset of illness

| Days after onset* | PRNT | | | Spike RBD ELISA | |
|-------------------|-----------|------------------------------|------------------------------|-----------------|--------------------|
| | No tested | PRNT90 No (%) positive | PRNT50 No (%) positive | No tested | No (%) positive |
| 0-7 | 35 | 11 (31%) | 12 (34%) | 9 | 2 (22%) |
| 8-14 | 24 | 21 (88%) | 23 (96%) | 13 | 9 (69%) |
| 15-21 | 15 | 15 (100%) | 15 (100%) | 14 | 14 (100%) |
| 22-28 | 11 | 11 (100%) | 11 (100%) | 10 | 10 (100%) |
| 29-60 | 93 | 91 (98%) | 93 (100%) | 84 | 84 (100%) |
| 61-90 | 54 | 54 (100%) | 54 (100%) | 43 | 43 (100%) |
| 91-150 | 35 | 34 (97%) | 34 (97%) | 16 | 32 (100%) |
| 151-209 | 26 | 26 (100%) | 26 (100%) | 26 | 26 (100%) |

* For asymptomatic individuals, days after first positive RT-PCR result.

Supplementary figure 1. Correlation between PRNT₉₀, and ELISA (left) and PRNT₅₀ and ELISA (right) in COVID-19 patients (n=231 pairs)

